Welcome to our dedicated page for PALISADE BIO SEC filings (Ticker: PALI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Palisade Bio, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing oral PDE4 inhibitor prodrugs. Disclosures include proxy materials for annual and special stockholder meetings, director elections, auditor ratification, charter-amendment voting matters and compensation-plan governance.
Material-event reports and registration statements cover clinical-development service arrangements, common-stock sales, securities registration, capital-structure updates, Nasdaq listing compliance and meeting adjournment or withdrawal actions. The filings also provide formal context for PALI-2108 development activities, equity financing mechanics, corporate governance and public-company reporting obligations.
PALISADE BIO, INC. (PALI) reported that its CEO and CFO, John David Finley, made an internal reallocation of holdings through bona fide gifts of common stock on August 19, 2026. He transferred 88,400 shares of common stock from his direct ownership to FCW Investments, LLC, an entity he manages.
After these related gift transactions, Finley directly holds 129,288 shares of Palisade Bio common stock and indirectly holds 88,451 shares through FCW Investments, LLC, over which he has sole investment and voting power. The Rule 10b5-1 trading plan checkbox was not marked for these transactions.
Palisade Bio, Inc. is reported by Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz as a group holding no beneficial ownership of its common stock. Each filer reports 0.00 shares with 0.0% of the class and no sole or shared voting or dispositive power. The group also confirms ownership of 5 percent or less of Palisade Bio’s common stock.
Palisade Bio, Inc. received an amended Schedule 13G reporting that Soleus Capital Master Fund, L.P. and related Soleus entities collectively report beneficial ownership of 13,063,687 shares of Palisade Bio common stock. Based on 174,270,558 shares outstanding as of August 6, 2026, this represents 7.5% of the company’s common stock.
The filing lists zero sole voting and dispositive power and 13,063,687 shares of shared voting and shared dispositive power for each reporting person. The shares are held directly by Soleus Capital Master Fund, L.P., with several affiliated Soleus entities and Guy Levy reported as having shared power through their roles, while each disclaims beneficial ownership beyond Section 13(d) reporting purposes.
Palisade Bio reported second quarter 2026 results and progress on its lead IBD candidate PALI-2108. The company highlighted favorable Phase 1 safety, exposure and pharmacodynamic data, with all 5 ulcerative colitis patients showing clinical response and 2 achieving remission, and a roughly 47.5% mean SES-CD reduction in fibrostenotic Crohn’s disease patients.
PALI-2108 is advancing into Phase 2 trials: the ASCENTRA-UC study is expected to start in the second half of 2026 with primary efficacy results in the second half of 2027, and an IND for the ASCENTRA-CD Phase 2 trial is planned for the second half of 2026, with primary readout in early 2028. For the quarter ended June 30, 2026, Palisade reported $0.5 million in license revenue, research and development expenses of $7.4 million, general and administrative expenses of $4.8 million and a net loss of $10.6 million or $0.05 per share. Cash and cash equivalents were $125.2 million as of June 30, 2026, which the company believes will fund operations through the planned Phase 2 efficacy readouts.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company developing PALI-2108 for inflammatory bowel disease, advancing from Phase 1 into global Phase 2 programs (ASCENTRA-UC and planned ASCENTRA-CD). In June 2026, the FDA cleared an IND for the ASCENTRA-UC Phase 2 trial, with first patient enrollment expected in the second half of 2026.
For the three months ended June 30, 2026, the company reported $0.5 million of license revenue, all from a milestone under the Newsoara co-development agreement. Research and development expenses rose to $7.4 million and general and administrative expenses to $4.8 million, driven largely by higher headcount, program spending on PALI-2108, and significantly higher stock-based compensation. Net loss for the quarter was $10.6 million, and $20.2 million for the first six months of 2026.
Cash, cash equivalents and restricted cash totaled $125.2 million at June 30, 2026, down modestly from $133.4 million at year-end 2025. Management states this balance is sufficient to fund operations through key Phase 2 efficacy readouts in UC and CD into early 2028. The company continues to disclose a longstanding material weakness in internal control over financial reporting related to segregation of duties and formalized close processes, though it believes its financial statements are fairly presented.
BlackRock, Inc. reports beneficial ownership of common stock of Palisade Bio, Inc. as of June 30, 2026. BlackRock and certain of its business units collectively beneficially own 10,436,760 shares of Palisade Bio common stock, representing 6.0% of the class.
BlackRock has sole voting power over 10,326,107 shares and sole dispositive power over 10,436,760 shares, with no shared voting or dispositive power. Various underlying clients may receive dividends or sale proceeds, but no single client holds more than five percent of the outstanding common shares.
PALISADE BIO, INC. director Robert Baltera Jr. reported two open-market purchases of Common Stock. He bought 20,000 shares on July 8, 2026 at a weighted average price of $1.9899 per share, and 25,000 shares on July 9, 2026 at a weighted average price of $1.9560 per share. Following these transactions, he directly holds 461,904 shares. Each daily price is a weighted average of multiple trades within the stated intraday price ranges.
Palisade Bio director Robert Baltera Jr. reported open-market purchases of a total of 50,000 shares of common stock. He bought 20,000 shares on July 6, 2026 at a weighted average price of $2.052 per share and 30,000 shares on July 7, 2026 at a weighted average price of $2.0348 per share. The filing notes the trades were executed in multiple transactions within price ranges of $2.04–$2.068 and $2.00–$2.07. Following these purchases, Baltera directly owns 416,904 shares of Palisade Bio common stock.
Palisade Bio Chief Medical Officer Mitchell Lawrence Jones reported routine equity compensation activity involving restricted stock units (RSUs) and related tax sales. On July 6, he exercised 131,167 RSUs into an equal number of common shares at a stated price of $0.00 per share, reflecting settlement of vested awards granted on February 9, 2026. As part of this vesting, 51,880 common shares were sold at a weighted average price of $2.0535 per share solely to cover tax withholding obligations, with individual sale prices ranging from $2.045 to $2.06. Following these transactions, Jones directly holds 94,009 shares of common stock and 655,833 RSUs, which continue to vest with 1/6 of the RSUs scheduled to vest on July 6, 2026 and the remainder vesting quarterly over the next 10 quarters, subject to his continued service. His holdings also include 1,459 shares acquired under the company’s Employee Stock Purchase Plan on May 20, 2026.
PALISADE BIO, INC. CEO and CFO John David Finley reported routine equity compensation activity, including RSU settlement, warrant exercise, and a related share sale to cover taxes. On July 6–7, 2026, he acquired 335,167 common shares through vested Restricted Stock Units and 133 shares via exercise of a Series 2 warrant at $0.70 per share. He then sold 146,798 common shares at a weighted average price of $2.0664 per share solely to satisfy tax withholding obligations tied to the RSU vesting. After these transactions, he holds 217,688 common shares directly and 51 shares indirectly through FCW Investments, LLC, over which he has sole voting and investment power.